ArticleJournal of clinical medicine2019
The State of Lupus Clinical Trials: Minority Participation Needed.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- "What do you want this information for?": cognitive interviews with arthritis researchers to inform the development of a health equity-focused demographic survey for outcomes research.BMC rheumatology · 2026Article
- "It's Just Good Science": A Qualitative Study Exploring Equity, Diversity, and Inclusion in Canadian Arthritis Research.Arthritis care & research · 2025Article
- Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA.Lupus science & medicine · 2025Article
- Article
- Systemic lupus in the era of machine learning medicine.Lupus science & medicine · 2024Review
- Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.The Journal of rheumatology · 2024Article
- An intersectionality framework for identifying relevant covariates in health equity research.Frontiers in public health · 2024Review
- Feasibility and Utility of a Pilot Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials: Implementation and Evaluation in a Multisite Model Within a Lupus Clinical Trials Network.ACR open rheumatology · 2023Article
- Lupus clinical trials and the promise of future therapies.Rheumatology and immunology research · 2023Article
- Barriers and strategies for recruiting participants who identify as racial minorities in musculoskeletal health research: a scoping review.Frontiers in public health · 2023Article
- EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical Trials.ACR open rheumatology · 2022Article
- Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR).Lupus science & medicine · 2021Article
- Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.Trends in molecular medicine · 2021Review
- Increasing Ancestral Diversity in Lupus Trials: Ways Forward.Rheumatic diseases clinics of North America · 2020Review
- Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers.Lupus science & medicine · 2020Article
- 'Information is power': A qualitative exploration of co-producing education resources about cardiovascular disease in partnership with women living with lupus.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States, the reported prevalence of lupus is 100,000 to 500,000 patients. Lupus disproportionately affects minority populations, including African Americans and Latinos, and the associated health disparities are substantial. Women are at a higher risk of lupus than men and lupus prevalence is the highest in African Americans and Latinos compared to non-Hispanic whites. African Americans and Latinos also have increased disease symptom severity, experience more lupus-related complications, and have a two- to three-fold mortality rate compared to non-Hispanic Whites. Lupus clinical trials offer opportunities for quality care and can result in new treatment options, but African Americans and Latinos are underrepresented in clinical trials because of substantial patient- and provider-side barriers. In conjunction with the limited knowledge of clinical trials that potential participants may have, the healthcare staff approaching participants have limited time to adequately educate and explain the aspects of clinical trials. Indeed, ninety percent of clinical trials fail to meet their recruitment goals on time, so a multi-faceted approach is necessary to address the issue of low minority participation in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.